BNP Paribas Financial Markets Acquires 52,414 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

BNP Paribas Financial Markets increased its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2,640.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,399 shares of the company’s stock after purchasing an additional 52,414 shares during the period. BNP Paribas Financial Markets owned 0.15% of Lifecore Biomedical worth $268,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. DCF Advisers LLC grew its stake in Lifecore Biomedical by 2.1% in the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after purchasing an additional 6,000 shares during the last quarter. Allegheny Financial Group LTD purchased a new position in shares of Lifecore Biomedical in the 2nd quarter worth approximately $52,000. Renaissance Technologies LLC purchased a new position in shares of Lifecore Biomedical in the 2nd quarter worth approximately $56,000. Creative Planning bought a new position in shares of Lifecore Biomedical during the 3rd quarter worth approximately $69,000. Finally, Legion Partners Asset Management LLC lifted its position in Lifecore Biomedical by 0.6% during the second quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after acquiring an additional 18,182 shares during the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Lifecore Biomedical

In other news, major shareholder Wynnefield Partners Small Cap bought 122,930 shares of the stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average cost of $4.10 per share, with a total value of $504,013.00. Following the purchase, the insider now directly owns 2,095,783 shares in the company, valued at $8,592,710.30. The trade was a 6.23 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 28.21% of the company’s stock.

Analysts Set New Price Targets

LFCR has been the subject of several analyst reports. Craig Hallum increased their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd. Barrington Research downgraded Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 28th.

Lifecore Biomedical Stock Up 0.4 %

NASDAQ:LFCR opened at $7.61 on Monday. The firm has a market capitalization of $280.25 million, a P/E ratio of 95.13 and a beta of 0.99. The company’s fifty day moving average price is $6.31 and its 200-day moving average price is $5.61. Lifecore Biomedical, Inc. has a 1-year low of $3.68 and a 1-year high of $8.90. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Friday, October 4th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.07). Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. The company had revenue of $24.71 million for the quarter, compared to analysts’ expectations of $23.30 million. As a group, equities research analysts anticipate that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.